Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Efficacy and Safety Study of 2 Dose Levels of Subcutaneous Anakinra (Kineret) in Patients With Still's Disease (SJIA and AOSD)

X
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Efficacy and Safety Study of 2 Dose Levels of Subcutaneous Anakinra (Kineret) in Patients With Still's Disease (SJIA and AOSD)

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anakinra (Primary)
  • Indications Adult-onset Still's disease; Juvenile rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms anaSTILLs
  • Sponsors Swedish Orphan Biovitrum
  • Most Recent Events

    • 06 Jun 2020 Results presented at the 21st Annual Congress of the European League Against Rheumatism
    • 24 Apr 2019 Status changed from recruiting to discontinued, according to the Swedish Orphan Biovitrum media release.
    • 24 Apr 2019 According to the Swedish Orphan Biovitrum media release, after careful consideration and evaluation company decided to end enrolment and discontinue the study. The study will be completed according to plan for the patients enrolled.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top